MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bph.15898

Медицинская библиотека · British journal of pharmacology · 2022

Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.

González-Sánchez Elena, Muñoz-Callejas Antonio, Gómez-Román Javier, San Antonio Esther, Marengo Alessandro, Tsapis Nicolas, Bohne-Japiassu Kamila, González-Tajuelo Rafael, Pereda Saray, García-Pérez Javier, Cavagna Lorenzo, González-Gay Miguel Ángel, Vicente-Rabaneda Esther Francisca, Meloni Federica, Fattal Elias, Castañeda Santos, Urzainqui Ana

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin initiates leukocyte extravasation and deletion of the corresponding gene (Selplg) induces a SSc-like syndrome with high incidence of ILD in aged mice.

EXPERIMENTAL APPROACH: Aged PSGL-1 KO (Selplg-/- ) mice were used to assess the therapeutic effects of nanotherapy with everolimus, included in liposomes decorated with high MW hyaluronic acid (LipHA+Ev) and administered intratracheally to specifically target CD44-expressing lung cells.

KEY

RESULTS

PSGL-1 KO mice had increased numbers of CD45+ and CD45- cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45- cells expressing pro-inflammatory and pro-fibrotic cytokines were also increased. Lungs from PSGL-1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels.

CONCLUSIONS AND IMPLICATIONS: In PSGL-1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc-ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs.

Для цитирования: González-Sánchez Elena, Muñoz-Callejas Antonio, Gómez-Román Javier, San Antonio Esther, Marengo Alessandro, Tsapis Nicolas, Bohne-Japiassu Kamila, González-Tajuelo Rafael, Pereda Saray, García-Pérez Javier, Cavagna Lorenzo, González-Gay Miguel Ángel, Vicente-Rabaneda Esther Francisca, Meloni Federica, Fattal Elias, Castañeda Santos, Urzainqui Ana. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.. British journal of pharmacology. 2022. DOI: 10.1111/bph.15898.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.